Towa Pharmaceutical Co., Ltd.
TSE:4553 Lagerbericht
Marktkapitalisierung: JP¥152.6b
Towa Pharmaceutical Vergangene Ertragsentwicklung Wir sind noch dabei, den letzten Ergebnisbericht dieses Unternehmens zu bearbeiten
Vergangenheit Kriterienprüfungen 4/6 Towa PharmaceuticalDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -8.2% zurückgegangen, während in der Branche Pharmaceuticals die Gewinne wachsen. Die Umsatzerlöse sind gewachsen mit einer durchschnittlichen Rate von 16.6% pro Jahr. Towa Pharmaceutical Die Eigenkapitalrendite des Unternehmens beträgt 10.4%, und die Nettomargen liegen bei 7.2%.
Wichtige Informationen
-8.2%
Wachstumsrate der Gewinne
Pharmaceuticals Wachstum der Industrie 3.4% Wachstumsrate der Einnahmen 16.6% Eigenkapitalrendite 10.4% Netto-Marge 7.2% Nächste Ertragsaktualisierung 15 Nov 2024
Jüngste Aktualisierungen vergangener Leistungen
Towa Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 12, 2024 Sep 05
First quarter 2025 earnings: EPS and revenues exceed analyst expectations Aug 09
Towa Pharmaceutical's (TSE:4553) Earnings Are Weaker Than They Seem Jul 03
Towa Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 08, 2024 Jun 26
Full year 2024 earnings: EPS exceeds analyst expectations May 18
Towa Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024 Mar 02
Alle Updates anzeigen
Upcoming dividend of JP¥30.00 per share Sep 20
Towa Pharmaceutical (TSE:4553) Will Pay A Dividend Of ¥30.00 Sep 05
Towa Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 12, 2024 Sep 05
Consensus EPS estimates increase by 11% Aug 23
Towa Pharmaceutical (TSE:4553) Is Due To Pay A Dividend Of ¥30.00 Aug 15
First quarter 2025 earnings: EPS and revenues exceed analyst expectations Aug 09
Investor sentiment deteriorates as stock falls 16% Aug 05
Fewer Investors Than Expected Jumping On Towa Pharmaceutical Co., Ltd. (TSE:4553) Aug 03
Final dividend of JP¥30.00 announced Jul 11
Towa Pharmaceutical's (TSE:4553) Earnings Are Weaker Than They Seem Jul 03
New minor risk - Earnings quality Jul 03
Less than half of directors are independent Jun 29
Towa Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 08, 2024 Jun 26 Towa Pharmaceutical Co., Ltd. Files New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for the Rivastigmine Twice Weekly Transdermal Patch for Treating Mild to Moderate Dementia Associated with Alzheimer's Disease Jun 08
Towa Pharmaceutical Co., Ltd. Announces Board and Committee Resignations May 23
Price target decreased by 8.1% to JP¥3,393 May 23
Full year 2024 earnings: EPS exceeds analyst expectations May 18
Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024 May 16
Upcoming dividend of JP¥30.00 per share Mar 21
Price target increased by 7.6% to JP¥3,690 Mar 09
Towa Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024 Mar 02
Consensus EPS estimates increase by 38% Feb 21
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Feb 14
Investor sentiment improves as stock rises 20% Feb 14
Towa Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 13, 2024 Dec 28
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 15
Price target increased by 12% to JP¥3,150 Oct 28
Towa Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 13, 2023 Oct 05
Upcoming dividend of JP¥30.00 per share at 2.1% yield Sep 21
Price target increased by 18% to JP¥2,228 Aug 22
Consensus EPS estimates increase by 14% Aug 17
Investor sentiment improves as stock rises 18% Aug 17
New minor risk - Share price stability Aug 15
First quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 12
Less than half of directors are independent Jul 15
Towa Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 10, 2023 Jun 17
New major risk - Dividend sustainability Jun 12
Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023 May 17
Full year 2023 earnings: EPS and revenues miss analyst expectations May 17
Upcoming dividend of JP¥30.00 per share at 3.2% yield Mar 23
Price target decreased by 11% to JP¥2,120 Mar 18
Price target decreased by 13% to JP¥2,370 Feb 16
Third quarter 2023 earnings released: JP¥14.38 loss per share (vs JP¥117 profit in 3Q 2022) Feb 14
Towa Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 13, 2023 Dec 28
Consensus EPS estimates fall by 13% Nov 29
Consensus EPS estimates fall by 19% Nov 21
Less than half of directors are independent Nov 16
Upcoming dividend of JP¥30.00 per share Sep 22
Towa Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 14, 2022 Sep 02
First quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 12
Price target decreased to JP¥2,800 Jul 09
Towa Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 10, 2022 Jun 29
Price target decreased to JP¥3,167 Jun 07
Full year 2022 earnings: EPS and revenues miss analyst expectations May 16 Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2022 May 15
Less than half of directors are independent Apr 27
Towa Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022 Apr 04
Upcoming dividend of JP¥33.00 per share Mar 23
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 20
Second quarter 2022 earnings released: EPS JP¥79.88 (vs JP¥59.25 in 2Q 2021) Nov 16
Investor sentiment deteriorated over the past week Oct 28
Price target increased to JP¥3,364 Sep 30
Upcoming dividend of JP¥27.00 per share Sep 22
Price target increased to JP¥3,084 Sep 02
First quarter 2022 earnings released: EPS JP¥108 (vs JP¥67.77 in 1Q 2021) Aug 18
Full year 2021 earnings released: EPS JP¥284 (vs JP¥295 in FY 2020) May 17
Upcoming dividend of JP¥22.00 per share Mar 23
Towa Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 14, 2021 Mar 07
Luye Pharma Switzerland AG and Towa Pharmaceutical Co., Ltd. Enters Strategic Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan Feb 18
New 90-day high: JP¥2,237 Feb 15
Third quarter 2021 earnings released: EPS JP¥64.94 (vs JP¥79.32 in 3Q 2020) Feb 14
Revenue and earnings beat expectations Feb 14
New 90-day high: JP¥2,093 Jan 29
New 90-day low: JP¥1,862 Dec 07
Towa Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 12, 2021 Nov 29
Towa Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Nov 13, 2020 Aug 30
Aufschlüsselung der Einnahmen und Ausgaben
Wie Towa Pharmaceutical Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie TSE:4553 Einnahmen, Ausgaben und Erträge (JPY Millions) Datum Einnahmen Umsatz Allgemeine und Verwaltungskosten F&E-Ausgaben 30 Jun 24 235,952 16,918 65,493 0 31 Mar 24 227,934 16,173 50,493 13,242 31 Dec 23 236,779 11,735 53,438 15,265 30 Sep 23 225,755 6,462 53,217 15,265 30 Jun 23 218,035 5,556 53,120 15,265 31 Mar 23 208,859 2,201 51,934 15,265 31 Dec 22 180,407 2,898 49,087 11,488 30 Sep 22 173,861 9,364 45,048 11,488 30 Jun 22 168,060 11,998 42,720 11,488 31 Mar 22 165,615 15,914 40,160 11,488 31 Dec 21 165,262 19,511 38,353 10,642 30 Sep 21 162,514 16,949 37,403 10,642 30 Jun 21 159,927 15,934 35,722 10,642 31 Mar 21 154,900 13,958 34,881 10,642 31 Dec 20 141,230 12,981 34,253 8,566 30 Sep 20 129,674 13,688 31,546 8,566 30 Jun 20 119,878 14,074 29,137 8,566 31 Mar 20 110,384 14,503 25,909 8,566 31 Dec 19 111,218 13,989 25,475 7,916 30 Sep 19 111,315 14,364 25,296 7,916 30 Jun 19 108,016 13,673 24,198 7,916 31 Mar 19 105,104 13,475 24,200 7,916 31 Dec 18 101,309 9,577 23,732 7,725 30 Sep 18 97,871 8,369 23,652 7,725 30 Jun 18 96,411 8,056 24,194 7,725 31 Mar 18 93,430 6,495 23,682 7,725 31 Dec 17 91,660 8,145 22,472 9,352 30 Sep 17 89,126 9,794 22,301 9,352 30 Jun 17 87,285 8,680 22,481 9,352 31 Mar 17 84,949 5,576 22,552 9,352 31 Dec 16 84,582 6,180 23,411 8,924 30 Sep 16 83,474 3,755 23,500 8,924 30 Jun 16 82,862 4,345 22,657 8,924 31 Mar 16 82,115 7,684 21,795 8,924 31 Dec 15 79,649 8,521 23,259 6,144 30 Sep 15 77,164 11,064 22,008 6,144 30 Jun 15 74,414 12,076 20,464 6,144 31 Mar 15 71,470 11,118 19,723 6,144 31 Dec 14 69,181 9,758 19,258 5,296 30 Sep 14 66,260 8,041 18,373 5,296 30 Jun 14 63,232 6,075 18,126 5,296 31 Mar 14 61,351 5,992 17,144 5,296 31 Dec 13 58,762 6,342 17,163 4,478
Qualität der Erträge: 4553 hat hohe Qualitätseinkünfte .
Wachsende Gewinnspanne: 4553Die aktuellen Gewinnspannen (7.2%) sind höher als im letzten Jahr (2.5%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 4553Die Erträge des Unternehmens sind in den letzten 5 Jahren um 8.2% pro Jahr zurückgegangen.
Beschleunigtes Wachstum: 4553Das Gewinnwachstum des Unternehmens im letzten Jahr (204.5%) übertrifft seinen 5-Jahres-Durchschnitt (-8.2% pro Jahr).
Erträge im Vergleich zur Industrie: 4553 Das Gewinnwachstum im vergangenen Jahr (204.5%) übertraf das der Branche Pharmaceuticals 16.2% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 4553Die Eigenkapitalrendite des Unternehmens (10.4%) wird als niedrig angesehen.
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}